Evidence map›Paper›PMID 42365239›Full record

ArticleBMC geriatrics2026

Which assessment tools best distinguish between mild cognitive impairment and dementia? Lessons from a Slovak memory clinic cohort.

Petr Novak, Stanislav Katina, Petra Brandoburova, Michaela Jezberova, Veronika Reznakova, Jozef Hanes, Frantisek Jurcaga, Peter Koson, Michal Novak, Linus Jönsson and 1 more

Abstract read
In one paragraph

Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Petr NovakInstitute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia. petr.novak@savba.sk.
Stanislav KatinaInstitute of Mathematics and Statistics, Masaryk University, Brno, Czech Republic.
Petra BrandoburovaMEMORY Centre n.o, Bratislava, Slovakia.
Michaela JezberovaDr. Magnet s.r.o, Bratislava, Slovakia.
Veronika ReznakovaMEMORY Centre n.o, Bratislava, Slovakia.
Jozef HanesInstitute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.
Frantisek JurcagaNeurological Clinic of the Faculty of Medicine SZU and UN of St. Michael, a. s, Bratislava, Slovakia.
Peter KosonNeurological Clinic of the Faculty of Medicine SZU and UN of St. Michael, a. s, Bratislava, Slovakia.
Michal NovakInstitute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.
Linus JönssonDepartment of Neurobiology, Care and Society, Karolinska Institutet, Solna, Sweden.
Norbert ZilkaInstitute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia. norbert.zilka@savba.sk.

Funding

Agentúra na Podporu Výskumu a Vývoja 20-0447EU Joint Programme - Neurodegenerative Disease Research ADDITION: Alzheimer's disease data-driven insights on individual outcomes of importance
6 · The paper itself

Abstract

backgroundThe utility of various cognitive assessment tools for distinguishing between mild impairment and dementia, as well as for determining cutoff values for specific populations, continues to be the subject of extensive research. Here, we assessed the utility and feasibility of these tools in the first Slovak memory clinic cohort.

methodsWe enrolled a Slovak memory clinic cohort of patients with MCI and dementia (MCI, n = 84; dementia, n = 55). The participants were characterized using a range of cognitive assessment tools-Auditory Verbal Learning (AVLT), Category and Letter Fluency (CFT, LFT), Digit Span (DSF, DSB), Digit-Symbol Coding (DS-C), Frontal Assessment Battery (FAB), MMSE, MoCA, Rey Osterrieth Complex Figure (ROCF), and Trail Making Test (TMTA, TMTB); clinical assessments-Amsterdam Instrumental Activities of Daily Living (A-IADL) and 5-level EuroQol questionnaire with 5 dimensions (EQ-5D-5 L); and scales for anxiety, dependency, depression, dignity, and MRI volumetry. The ability of the various assessments to distinguish between MCI and dementia was evaluated.

resultsOver the course of three years, at a single memory clinic, it was feasible to enrol and evaluate a total of 150 participants, 139 of whom fulfilled the definition of either MCI or nonvascular dementia. Of the employed cognitive and clinical assessment tools, the best differentiation between MCI and dementia was observed for the AVLT and A-IADL. The DSF and DSB tests did not reveal differences between the populations. No differences were observed in education, vital signs, or anthropometric measurements. Participants with dementia had greater degrees of brain atrophy in the hippocampi and frontal, parietal, and temporal cortex; lower total brain volumes; and greater ventricular dilation.

conclusionsThis study confirms the utility of a range of cognitive assessment tools and scales for differentiating between MCI and dementia but reveals that some commonly employed tools, such as the DSF and DSB, may not be sensitive to these differences. This study highlights the importance of accurate assessment of the ability to perform activities of daily living and supports the development of objective, ecologically valid assessments of IADL.

Indexed as

Cognitive DysfunctionDementiaMemoryNeuropsychological TestsActivities of Daily LivingAgedAged, 80 and overCohort StudiesDiagnosis, DifferentialFemaleHumansMaleSlovakiaAlzheimer’s diseasemild cognitive impairmentneuropsychologyobservational study

Identifiers

PMID42365239
PMCPMC13576276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.